The earnings call reflects a positive sentiment due to Vertex's strong revenue growth, successful product launches, and advancements in its pipeline. However, challenges in the pain program and increased operational expenses present notable concerns.

Company Guidance -

Q3 2025

In the second quarter of 2025, Vertex Pharmaceuticals reported $2.96 billion in revenue, marking a 12% increase compared to Q2 2024. This growth was driven by multiple new product launches, including ALYFTREK for cystic fibrosis (CF) and JOURNAVX for acute pain. ALYFTREK contributed to a 14% increase in U.S. revenue, as it is now approved and reimbursed in several countries. JOURNAVX secured coverage for approximately 150 million lives in the U.S., with 84 million having unrestricted access. CASGEVY, a gene-edited therapy for sickle cell disease and beta thalassemia, also showed growth, with 29 patients receiving infusions by the end of Q2. Vertex maintained its revenue guidance for 2025 at $11.85 billion to $12 billion, reflecting confidence in its CF portfolio and new product contributions. The company is advancing several clinical programs, including those for type 1 diabetes and various kidney diseases, with potential regulatory submissions expected in 2026.

Strong Revenue Growth

Vertex delivered $2.96 billion in revenue in Q2 2025, representing a 12% growth compared to Q2 2024. U.S. revenue growth was 14% year-over-year, driven by ongoing patient demand and favorable gross to net, along with contributions from CASGEVY, JOURNAVX, and collaboration revenue.

Successful Product Launches

Vertex launched multiple new products, including ALYFTREK for cystic fibrosis, JOURNAVX for acute pain, and CASGEVY for sickle cell disease and beta thalassemia. The launch of ALYFTREK in the U.S. is progressing well, particularly for patients naive to CFTR modulators.

Pipeline Advancements

Vertex advanced several programs, including the NG 3.0 regimen for cystic fibrosis with VX-828 and type 1 diabetes treatment zimislecel. The company is also prioritizing clinical-stage programs in renal diseases and achieved positive regulatory feedback for future developments.

Positive Financial Position

Vertex ended the quarter with $12 billion in cash and investments and announced a new $4 billion share repurchase program, indicating strong financial health and commitment to shareholder returns.

Vertex Pharmaceuticals (VRTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VRTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	4.62 / -	4.38	―	―	―
Aug 06, 2025	2025 (Q2)	4.27 / 4.52	-12.83	135.23% (+17.35)
May 05, 2025	2025 (Q1)	4.25 / 4.06	4.76	-14.71% (-0.70)
Feb 10, 2025	2024 (Q4)	4.02 / 3.98	4.2	-5.24% (-0.22)
Nov 04, 2024	2024 (Q3)	4.08 / 4.38	4.08	7.35% (+0.30)
Aug 01, 2024	2024 (Q2)	-11.63 / -12.83	3.89	-429.82% (-16.72)
May 06, 2024	2024 (Q1)	4.07 / 4.76	3.05	56.07% (+1.71)
Feb 05, 2024	2023 (Q4)	4.07 / 4.20	3.76	11.70% (+0.44)
Nov 06, 2023	2023 (Q3)	3.93 / 4.08	4.01	1.75% (+0.07)
Aug 01, 2023	2023 (Q2)	3.86 / 3.89	3.6	8.06% (+0.29)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VRTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$385.65	$375.63	-2.60%
May 05, 2025	$500.19	$450.03	-10.03%
Feb 10, 2025	$469.97	$455.22	-3.14%
Nov 04, 2024	$472.80	$499.88	+5.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vertex Pharmaceuticals (VRTX) report earnings?

Vertex Pharmaceuticals (VRTX) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Vertex Pharmaceuticals (VRTX) earnings time?

Vertex Pharmaceuticals (VRTX) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VRTX EPS forecast?

VRTX EPS forecast for the fiscal quarter 2025 (Q3) is 4.62.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing